Moleculin Biotech, Inc. Share Price Today: Live Updates & Key Insights

Moleculin Biotech, Inc. share price today is $2.06, up 0%. The stock opened at $2.06 against the previous close of $2.06, with an intraday high of $2.12 and low of $2.01.

Moleculin Biotech, Inc. Share Price Chart

Moleculin Biotech, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Moleculin Biotech, Inc. Share Price Performance

$2.06 0(0%) MBRX at 23 Mar 2026 02:13 PM Biotechnology
Lowest Today 2.01
Highest Today 2.12
Today’s Open 2.06
Prev. Close 2.06
52 Week High 33.00
52 Week Low 1.79
Day’s Range: Low 2.01 High 2.12
52-Week Range: Low 1.79 High 33.00
1 day return -
1 Week return +0.49
1 month return -12.01
3 month return -49.38
6 month return +401.59
1 year return +95.23
3 year return -85.39
5 year return -96.76
10 year return -

Moleculin Biotech, Inc. Institutional Holdings

Citadel Advisors Llc 0.67

Jane Street Group LLC 0.46

Abante Quant Value FI 0.39

Vanguard Group Inc 0.32

Geode Capital Management, LLC 0.31

Fidelity Extended Market Index 0.23

Vanguard Institutional Extnd Mkt Idx Tr 0.19

NT Ext Equity Mkt Idx Fd - L 0.06

Tower Research Capital LLC 0.03

Spartan Total Market Index Pool G 0.03

Fidelity Series Total Market Index 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Fidelity Total Market Index 0.02

The Goldman Sachs Group Inc 0.01

BlackRock Inc 0.01

EFG International AG 0.01

BB&T Corp. 0.01

Rockefeller Capital Management L.P. 0.00

UBS Group AG 0.00

Newbridge Financial Services Group, Inc. 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Morgan Stanley - Brokerage Accounts 0.00

Spartan Extended Market Index Pool F 0.00

SBI Securities Co Ltd 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Vanguard U.S. Eq Idx £ Acc 0.00

SSgA U.S. Total Market Index Strategy 0.00

Bank of America Corp 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

Advisor Group Holdings, Inc. 0.00

Atlantic Union Bankshares Corp 0.00

CVA Family Office, LLC 0.00

Danske Bank A/S. 0.00

Ethos Financial Group LLC 0.00

Moleculin Biotech, Inc. Market Status

Strong Buy: 0

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Moleculin Biotech, Inc. Fundamentals

Market Cap 22.47 M

PB Ratio 225.3672

PE Ratio 0.0

Enterprise Value 3.95 M

Total Assets 22.13 M

Volume 79682

Moleculin Biotech, Inc. Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:-164000 -0.2M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-26270000 -26.3M, FY22:-27410000 -27.4M, FY21:-8860000 -8.9M, FY20:-14996000 -15.0M, FY19:-13205000 -13.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:63000 0.1M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-21000 -0.0M, Q2/2025:-29000 -0.0M, Q1/2025:-31000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-31000 -0.0M

Quarterly Net worth Q3/2025:-25399000 -25.4M, Q2/2025:-7640000 -7.6M, Q1/2025:-6436000 -6.4M, Q3/2024:-10592000 -10.6M, Q2/2024:-4319000 -4.3M

About Moleculin Biotech, Inc. & investment objective

Company Information Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. Walter V. Klemp

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Moleculin Biotech, Inc. FAQs

What is the share price of Moleculin Biotech, Inc. today?

The current share price of Moleculin Biotech, Inc. is $2.06.

Can I buy Moleculin Biotech, Inc. shares in India?

Yes, Indian investors can buy Moleculin Biotech, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Moleculin Biotech, Inc. shares in India?

You can easily invest in Moleculin Biotech, Inc. shares from India by:

Can I buy fractional shares of Moleculin Biotech, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Moleculin Biotech, Inc.?

Moleculin Biotech, Inc. has a market cap of $22.47 M.

In which sector does Moleculin Biotech, Inc. belong?

Moleculin Biotech, Inc. operates in the Biotechnology sector.

What documents are required to invest in Moleculin Biotech, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Moleculin Biotech, Inc.?

The PE ratio of Moleculin Biotech, Inc. is N/A and the PB ratio is 225.37.